"The parties also signed a license agreement for the tissue processing technology limited to the CardioCel and VascuCel product lines and a transition services agreement under which Admedus will continue to manufacture the products for up to three years while LeMaitre Vascular transitions manufacturing to its US headquarters."
From the Le Maitre website announcement. The license agreement terms are most likely commercial in confidence be one would expect some level of ongoing licence royalties.
Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular, page-137
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.20 |
Change
0.200(1.11%) |
Mkt cap ! $349.8M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.20 | $17.65 | $78.15K | 4.366K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 619 | $17.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.20 | 146 | 1 |
View Market Depth
| Last trade - 16.10pm 08/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |